🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — April 15, 2026

Across 39 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing compliance crises in 4 small-cap biotechs/techs (Soluna, Alaunos, BioCardia, Mainz with equity deficits from $641k-$2.15M vs $2.5M min), high debt/concentration risks (Strawberry Fields REIT $752M debt, 86.8% rent from 15 leases), and deleveraging actions via asset sales (Spire $650M, Owens Corning $645M EV post-impairment), debt settlements (Visium $182k, SUNation $1.2M conversion), and equity raises (Graham $50M, Traws $10M PIPE). Credit facility amendments/extensions (Flowserve $1.45B, Federal Realty $1.4B, Leidos/U.S. Physical Therapy) signal proactive liquidity management amid potential distress, with no broad YoY revenue/margin declines but equity erosion in biotechs. Positive M&A/JVs (Tilray Lyphe accretive 2027, Limoneira composting FY2027) offer turnaround plays. Portfolio-level: 12/39 show debt reduction/capital inflows vs 7 Nasdaq risks; implications: short Nasdaq non-compliant, long deleveraging industrials/utilities.

39 high priority 39 total filings
· daily

US Executive Officer Management Changes SEC — April 15, 2026

Across 29 filings on US executive and director changes from April 2026, the dominant theme is leadership transitions with 14 appointments/promotions (48%), 11 resignations/departures (38%), 3 compensation enhancements, and 1 CEO return from medical leave, signaling a mix of proactive team-building in biotech/energy and reactive stability measures amid M&A. Positive sentiment prevails in 8 filings (28%), particularly biotechs (Structure Therapeutics, Prelude, Tango) hiring for Phase 3/clinical catalysts and media (Cineverse, Regis) for growth strategies, while 17 neutrals (59%) reflect routine no-disagreement exits; no explicit YoY revenue/margin declines but comp increases (e.g., Hallador CEO +18.5% YoY base) indicate retention amid $68M EBITDA targets. Portfolio-level patterns show healthcare/biotech outliers with experienced hires boosting pipelines (e.g., 30+ years oncology exp at Prelude), contrasting finance/industrials' interim roles (Corebridge, Kenvue pre-merger). Critical implications include M&A risks (Corebridge $385B AUM merger), board contractions (DuPont 11→10, American Vanguard 9→7 per debt terms), and 2026 catalysts like clinical data (Tango vopimetostat). No broad insider trading patterns but shareholder designees (Hagerty, Ribbon) suggest alignment; capital allocation leans retention via RSUs/sev (Lionsgate 4.5M options, Hallador $2.4M CIC). Actionable: Favor biotech hires for alpha, monitor interims for volatility.

29 high priority 29 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 15, 2026

Across 29 US SEC filings on boardroom changes (Apr 15, 2026 period), leadership churn dominates with 14 resignations/departures (e.g., CEOs at World Acceptance/Trans-Lux, CFOs at LENSAR/Corebridge/Kenvue, directors at Figma/OGE/ESS/DuPont/American Vanguard/Hagerty/USBC) and 13 appointments/promotions (strong in biotech: Structure/Prelude/Tango/Cineverse adding pipeline/ops expertise). Sentiment skews neutral (19/29) but positive in biotech/media (9/29) signaling strategic bolstering for trials/acquisitions; no uniform YoY/QoQ financial trends but comp hikes (Hallador CEO +18.5% to $800k, $68M Adj EBITDA target) and equity grants (Lionsgate $10M annual) reflect confidence. Insider-linked activity minimal but shareholder designees (Hagerty/Ribbon) and major holder reps (Regis) indicate alignment. Forward catalysts cluster Q2 2026 (clinical data, Phase 3 trials, mergers); portfolio trend: Biotech leadership upgrades for 2026 catalysts vs small-cap turnover risks. Implications: Favor biotech hires for alpha, monitor interims amid M&A (Corebridge/Kenvue), neutral on routine director exits.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — April 15, 2026

Across 9 SPAC filings in USA M&A & Takeover Activity, a dominant theme is deadline extensions and amendments in 6/9 cases (Pantages, Keen Vision, Ribbon, SIM, WinVest, indirectly Spring Valley), signaling sponsor commitment amid no completed deals, with total extension funding ~$335k via trust deposits and notes. Positive outliers include board expertise addition at Launchpad Cadenza and strategic tailings acquisition for Plum III's rare earth project (1.5M tons for 3M shares), contrasting mixed risks in Spring Valley's fusion merger. No YoY/QoQ operating trends available as pre-merger entities, but capital allocation trends show increasing sponsor loans/deposits (e.g., Ribbon $125k, WinVest $180k note with $60k drawn). Neutral-to-positive sentiment prevails (2 positive, 6 neutral, 1 mixed), with materiality highest (8/10) for active M&A updates. Portfolio-level pattern: SPAC sector under deadline pressure (original deadlines April-May 2026), driving activity spikes; implications include short-term upside on catalyst hits but redemption risks if unfulfilled. Forward-looking catalysts cluster late April, positioning for de-SPAC announcements.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 15, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with banks like M&T showing 14% YoY net income growth but 13% QoQ declines, telecoms like Chunghwa Telecom up 2.7% YoY revenues amid flat margins, and sharp contrasts in small caps (Veea losses narrowed 86% YoY vs Eightco's $262M net loss on 17% revenue drop). Biotech and SPAC activity surges with mergers (Galera-Obsidian all-stock deal, Pasqal quantum SPAC with $400M funding, FG Merger-BOXABL at $3.5B valuation), while restructuring dominates (Snap 16% headcount cut for $500M savings) and dilution risks loom in low-float names (Soluna Nasdaq warning, Lunai reverse split). Capital raises are bullish (TeraWulf $900M offering, Brookfield $1B notes), but portfolio-level trends show 5/15 high-materiality firms with YoY revenue declines averaging -15% (outliers: Sonim 0%, Tradewinds -22%). M&A tax clarifications (Mission Produce cap $5M) reduce risks, yet going concern doubts persist in 3 biotechs/dev firms. Institutional 13Fs (12 filings) indicate ETF-heavy portfolios (e.g., S&P 500, QQQ dominance) signaling broad market stability. Actionable: Favor energy/crypto raises and biotech catalysts over distressed small caps ahead of market open.

21 high priority 29 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 14, 2026

The FDA's approvals over the April 14, 2026 period (reflecting fallback actions from April 7-9) delivered 6 neutral 'other' approvals with 0 NMEs, 0 biosimilars, 0 label expansions, all carrying medium strength and materiality (5/10). These went to small-cap sponsors AUCTA (FOSFOMYCIN TROMETHAMINE), ASCENT PHARMS INC (MIRABEGRON), ZENARA (ELTROMBOPAG OLAMINE), RENATA LIMITED (Unknown), CHANGZHOU PHARMACEUTICAL FACTORY (VERICIGUAT), and APOTEX INC (SEMAGLUTIDE), each summarized as biosimilar approvals despite classification. No dominant therapeutic area theme emerges amid diverse molecules spanning urology, hematology, cardiovascular, endocrinology, and infectious disease. Highest-conviction signal is APOTEX INC's SEMAGLUTIDE approval, implying neutral commercial entry potential into GLP-1 arena with all key metrics NOT_DISCLOSED. Key risk/watch item: limited pipeline signals from single approvals per sponsor, raising questions on sustained execution.

6 total filings
· daily

Big Pharma Approvals — April 14, 2026

The April 14, 2026 period featured 1 Other approval (0 NMEs, 0 biosimilars, 0 label expansions) in the Big Pharma stream, generating 1 bullish signal. GENENTECH INC secured a label expansion for FARICIMAB-SVOA (VABYSMO), signaling portfolio strengthening though commercial details remain NOT_DISCLOSED. No dominant therapeutic area theme emerges from this single event. Highest-conviction signal is the bullish FARICIMAB-SVOA label expansion by GENENTECH INC, implying extended market reach for the sponsor. Key risk/watch item: monitor post-approval uptake given lack of disclosed peak sales, exclusivity, pricing, or market position data.

1 total filings
· daily

Orphan Drug Approvals — April 14, 2026

The period saw 1 orphan drug approval: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other, generating 1 bullish signal with no bearish or neutral outcomes. BRISTOL's AZACITIDINE (ONUREG) fallback approval (noted as label expansion) represents the highest-conviction signal, providing a moderate bullish catalyst (strength 5/10, materiality 5/10) for portfolio diversification in the orphan space. No dominant therapeutic area theme emerges from this single event. Key risk/watch item: limited disclosure on peak sales, exclusivity, pricing, and market position warrants monitoring for commercial uptake and competitive dynamics.

1 total filings
· daily

New Federal Contractors — April 14, 2026

Two new federal contracts totaling $186,887,051 in obligations, with 0/2 defense-related (100% civilian split across State Department and USAID), highlight overseas facilities support and international health services as the dominant theme. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 State Department award for Doha, Qatar facilities support, offering ~$32M annual revenue visibility through 2026 (or ~$27M if extended to $137M by 2028). RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID HIV services contract is neutral for equity investors due to its foreign nonprofit status despite $80.3M outlays. A key risk is Vectrus's low $668,474 outlays to date amid $53.6M subawards, warranting monitoring for execution progress.

2 total filings
· daily

Significant Contract Modifications ($10M+) — April 14, 2026

Two significant contract modifications totaling $186,887,051 in obligations, both civilian with zero defense exposure, highlight Department of State and USAID investments in international services. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96.7M Department of State award for facilities support in Doha, Qatar, offering multi-year revenue visibility up to $137M through 2028 if options are exercised. RIGHT TO CARE ZAMBIA LIMITED's $90.2M USAID HIV services contract is neutral for investors due to its nonprofit status and foreign ownership, despite high $80.3M outlays. Dominant theme is sustained civilian agency funding for overseas program management. Key watch item: Vectrus outlay progress beyond current $668K amid $53.6M subawards, signaling execution risk.

2 total filings
· daily

Contract Deobligations Alert — April 14, 2026

Two civilian agency contract deobligations totaling $186,887,051 were flagged for the period April 14, 2026, with zero defense-related awards, highlighting State Department and USAID facilities and health services themes. The highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 Department of State delivery order for Qatar facilities support, offering multi-year revenue visibility up to $137M with options despite low $668,474 outlays to date. RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID HIV services contract remains neutral for investors as a foreign-owned nonprofit with $80.3M already outlayed. Dominant themes are sustained civilian international program management, but low execution on the top contract poses execution risk. Key watch item: Vectrus outlay progress beyond $668,474 and option exercises toward 2026-04-30 or 2028-04-30 end dates.

2 total filings
· daily

Contract Option Exercises — April 14, 2026

Two civilian contract option exercises totaling $186,887,051 in obligations provide limited defense exposure (0/2 defense-related) with average signal strength of 4.0/10. The highest-materiality award is a bullish $96.7M obligation to Vectrus Systems LLC from the Department of State for facilities support in Doha, Qatar, offering multi-year revenue visibility up to $137M potential through 2028. USAID's $90.2M obligation to foreign nonprofit Right to Care Zambia Limited for HIV services is neutral due to its low materiality and nonprofit status limiting equity implications. Dominant theme is international civilian services support outside DOD priorities. Highest-conviction signal is bullish multi-year visibility for Vectrus amid low execution risk via cost-plus-fixed-fee structure. Key watch item is Vectrus outlay progress beyond current $668,474 amid $53.6M subawards.

2 total filings
· daily

Federal Professional Services Contracts — April 14, 2026

USAID/Zambia obligated $90,212,500 across one federal professional services contract to RIGHT TO CARE ZAMBIA LIMITED, representing 0% defense-related activity in the period. The dominant agency and sector theme is USAID international health funding for HIV prevention and treatment under the MECH program. The highest-conviction signal is neutral (strength 2/10, materiality 1/10) due to the recipient's status as a foreign-owned nonprofit with limited public equity implications. $80,280,560 has already been outlayed of the $90.2M obligation, with a ceiling of $121,447,869 including options. Key watch item: option exercises to expand beyond current obligation levels through performance end date of June 23, 2028.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 14, 2026

Two high-value civilian federal contracts totaling $186,887,051 in obligations were analyzed, with 0/2 defense-related and an average signal strength of 4.0/10. The dominant agencies are Department of State and USAID, focusing on international facilities support in Qatar and HIV prevention/treatment in Zambia. Highest-conviction bullish signal stems from Vectrus Systems LLC's $96,674,550 State Department award, offering multi-year revenue visibility estimated at ~$32M annually through 2026-04-30 or ~$27M if extended to $137M by 2028-04-30. RIGHT TO CARE ZAMBIA LIMITED's $90,212,500 USAID contract is neutral for equity investors as a foreign-owned nonprofit with $80.3M already outlayed. Key watch item: Vectrus Systems LLC outlay progress beyond current $668,474 amid high $53.6M subawards.

2 total filings
· daily

General Federal Contracts — April 14, 2026

Two civilian contracts totaling $186,887,051 in obligations were analyzed, with 0/2 defense-related, focusing on overseas support services via the Department of State and USAID. The highest-conviction signal is bullish on Vectrus Systems LLC's $96,674,550 Department of State delivery order for facilities support in Doha, Qatar, providing multi-year revenue visibility up to $137 million with options through 2028. RIGHT TO CARE ZAMBIA LIMITED's neutral $90,212,500 USAID contract for HIV services in Zambia carries limited equity implications as a foreign-owned nonprofit with $80.3 million already outlayed. Dominant theme is sustained civilian agency demand for international program management. Key watch item: Vectrus outlay progress beyond current $668,474 amid high $53.6 million subawards.

2 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority 8 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority 8 medium 17 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 14, 2026

Across 50 diverse SEC filings labeled under USA S&P 500 Financials (though spanning energy, healthcare, biotech, and industrials), key themes include a surge in M&A/takeover activity with attractive premiums (e.g., Avanos +72%, Day One $21.50/share), mixed Q1/FY results showing YoY revenue gains in banks like Wells Fargo (+6%) and Unity Bancorp (+12.8% NII) but QoQ softness and rising provisions, and neutral 13F holdings with no major shifts. Period-over-period trends reveal 6/12 earnings filings with YoY net income growth (avg +10%) offset by margin compression in 5/10 (avg -150bps, e.g., AstroNova -7.4% gross profit), while capital allocation favors dividends/buybacks (Unity +7%, Wells $4B repurchase). Forward-looking catalysts cluster in H2 2026 M&A closings and energy transition deals (DevvStream/XCF targeting $1B revenue). Portfolio-level, financials show loan/deposit growth (Unity +10.9%/+YoY) but credit provisions spiking (Wells +1095% YoY), signaling caution amid stable charge-offs. Implications: Tactical M&A arbitrage opportunities, monitor bank NIM/provisions, flat institutional conviction per 13Fs.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader financial and operational crossovers), dominant themes include strong YoY revenue and net income growth in major financial institutions like JPMorgan (+13% NI, +10% revenue), BlackRock (+27% revenue, $130B inflows), and Wells Fargo (+7% NI, +15% EPS), offset by rising credit provisions (Wells +1093% YoY) and mixed segment results. Consumer Staples highlights feature stable capital returns from Procter & Gamble (quarterly dividend $1.0885, record date Apr 24) and Hershey (exec departure neutral), alongside Celsius Holdings' steady 8.6-8.97% insider ownership amid proxy battles. Small-cap operators show sharp declines, e.g., Greystone Logistics sales -45% YoY 9M to $22M, Nature's Miracle revenue -97.6% YoY Q3, and Chipmos net profit -61.7% YoY amid margin compression to 10.8%. Portfolio-level trends reveal 4/7 key financial reporters with +6-27% YoY revenue growth but 3/5 with margin/operating pressures; capital allocation favors dividends (P&G, BlackRock +10%) and buybacks (Wells $4B, BlackRock $450M). Board/governance changes prevalent in 12/50 filings (e.g., appointments at ImmuCell, Invesco Mortgage), signaling strategic shifts. Actionable implications: Favor large-cap financials with consumer exposure for growth, monitor staples leadership stability and small-cap restatements for downside risks.

18 high priority 32 medium 50 total filings